Search
Shark liver oil
go.drugbank.com/drugs/DB11088ApprovedThe potential benefit of shark oil has been experimented in different therapeutic implications, where it is claimed to improve immune responses and exert an antitumor activity. … Shark oil is a rich source of alkylglycerols and squalene, with relatively low amounts of n-3 polyunsaturated fatty acids.
Foslevodopa
go.drugbank.com/drugs/DB16683ApprovedFoslevodopa is under investigation in clinical trial NCT04750226 (Study to Assess Adverse Events and Change in Disease Activity of 24-hour Continuous Subcutaneous Infusion of ABBV-951 in Adult Participants
C31G
go.drugbank.com/drugs/DB05398Investigationalis a potent broad spectrum antimicrobial agent, effective against gram positive and gram negative bacteria, yeast and fungi.C31G, vaginal gel is developed by Biosyn Inc. and has commenced enrollment in
Rebaudioside A
go.drugbank.com/drugs/DB15136InvestigationalRebaudioside A is under investigation in clinical trial NCT03510624 (Acute Effect of Rebaudioside A on Glucose Excursion During an Oral Glucose Tolerance Test in Type 2 Diabetes Mellitus).
XL019
go.drugbank.com/drugs/DB05243InvestigationalAn IND for XL019 was filed by Exelixis in May 2007.
Pozelimab
go.drugbank.com/drugs/DB15218ApprovedInvestigationalautoimmune hemolysis that are often observed in CHAPLE disease. … CD55-deficient protein-losing enteropathy (PLE), or CHAPLE disease, is an ultra-rare hereditary disease, with fewer than 100 patients diagnosed worldwide or fewer than 10 patients in the US.
Pucotenlimab
go.drugbank.com/drugs/DB17552ApprovedInvestigationalIt received its first global approval in China in July 2022 for the treatment of solid tumours.[A257296] It is being investigated in other cancers.
INGN 225
go.drugbank.com/drugs/DB05325InvestigationalINGN 225 is currently in Phase 1/2 trials in patients with small cell lung cancer and breast cancer. … INGN 225 is a therapeutic consisting of a cancer patient's own immune cells treated with an adenovector carrying the human p53 gene, Ad-p53.
TAS-106
go.drugbank.com/drugs/DB06656InvestigationalTAS-106 has demonstrated strong antitumor activity without serious toxicity in nude rat models bearing human tumours [A31693].